BE71F250-1529-43BD-84F3-3AFE1B42D77D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 16.491458607095925
- age_years
- 23
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.555
- MYC_TARGETS_V1+0.510
- CHOLESTEROL_HOMEOSTASIS+0.484
- MYC_TARGETS_V2+0.443
- E2F_TARGETS+0.396
- G2M_CHECKPOINT+0.392
- UNFOLDED_PROTEIN_RESPONSE+0.341
- ADIPOGENESIS+0.338
- MITOTIC_SPINDLE+0.338
- MTORC1_SIGNALING+0.336
Top 10 suppressed
- KRAS_SIGNALING_DN-0.342
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.235
- SPERMATOGENESIS-0.197
- MYOGENESIS-0.196
- ALLOGRAFT_REJECTION-0.132
- INTERFERON_GAMMA_RESPONSE-0.126
- ANGIOGENESIS-0.122
- COAGULATION-0.102
- ESTROGEN_RESPONSE_LATE-0.080
- INTERFERON_ALPHA_RESPONSE-0.072
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A0A24949-483B-4250-B11E-2BCE49F302AC | — | — | 0.922 |
| 2 | B7B9B5C1-C11D-47B8-B2F8-A5660AB961C1 | — | — | 0.908 |
| 3 | D0F8B6CA-5F3B-4B66-BCC5-72C17325DABF | — | — | 0.897 |
| 4 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.892 |
| 5 | SRR934969 | — | — | 0.891 |
| 6 | 63204446-7AA0-40DC-996D-440F4E19AD0F | — | — | 0.891 |
| 7 | 431CF176-101C-482F-B2A4-617ADF6475A8 | — | — | 0.891 |
| 8 | 6990AABF-A5F4-4784-91FF-286A0EE6A618 | — | — | 0.886 |
| 9 | 67B5E93E-6F06-4247-86DD-A914279EFFC5 | — | — | 0.884 |
| 10 | BE6A3670-34C4-4FD3-9794-C5B3254D9224 | — | — | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.555 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.484 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.443 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.396 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.392 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.341 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.338 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.338 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.336 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.323 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.315 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.304 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.263 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.262 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.247 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.217 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.195 | Inavolisib | — uncovered |
| PEROXISOME | 0.165 | Idelalisib | — uncovered |
| APOPTOSIS | 0.119 | Idelalisib | — uncovered |